Genocea Biosciences Names New CEO

Xconomy Boston — 

Genocea Biosciences, a Cambridge, MA-based firm that specializes in rapidly discovering potential vaccines, said today it has named Chip Clark as its new chief executive. Clark, who played a key role in the firm’s recent $35 million Series B financing, was previously the company’s chief business officer, a job he took in August 2010. He has been in the drug industry for more than 20 years, and prior to joining the company he was chief business officer of Vanda Pharmaceuticals in Rockville, MD. Staph Bakali, Genocea’s previous CEO, ended his stint as the firm’s chief executive in September.